Helena Strzelka
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Helena Strzelka has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
- Anna Zyskowska
Copernicus Medical Entity Ltd., Nicolaus Copernicus Hospital, Nowe Ogrody 1-6, 80-303 Gdańsk, Poland
3 shared publications - Bartosz Seroczyński
Independent Public Health Care Facility of the Ministry of Internal Affairs and Administration in Lublin, Grenadierów 3, 20-331 Lublin, Poland
3 shared publications - Jakub Marcel Korowicki
University Clinical Centre, Gdansk, Poland
3 shared publications - Julia Beata Woźniak
University Clinical Centre in Gdańsk, Dębinki 7, 80-952 Gdańsk, Poland
3 shared publications - Marta Labon
University Clinical Centre in Gdańsk, Dębinki 7, 80-952 Gdańsk, Poland
3 shared publications - Milena Dziedzina
University Clinical Centre in Gdańsk, Dębinki 7, 80-952 Gdańsk, Poland
3 shared publications
Latest Publications
- Open Access
- 11 October 2026
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Quality in Sport
- Vol. 77, 76234
The MIND Diet and Cognitive Health in Older Adults: Clinical Evidence, Neuroprotective Mechanisms and Research Gaps—A Narrative Review
Background. The MIND diet combines elements of the Mediterranean and DASH dietary patterns and was developed to support cognitive health. Evidence includes observational, randomised and experimental research. Aim. This narrative review evaluated associations between MIND diet adherence and cognitive outcomes in older adults and compared observational and randomised findings. Methods. PubMed, MEDLINE and Google Scholar were searched through August 2026. Studies addressing cognitive performance, cognitive decline, mild cognitive impairment or dementia were included. Experimental studies were used to assess biological plausibility. Findings were synthesised descriptively. Results. Most observational studies associated greater adherence with better global cognition and memory, slower cognitive decline and lower risks of cognitive impairment and dementia. Experimental evidence supports vascular, metabolic, antioxidant, anti-inflammatory, amyloid-related and gut–brain mechanisms. The principal three-year randomised trial found no significant cognitive or neuroimaging advantage over an active control. Both groups received dietary counselling and caloric restriction and experienced weight loss, while the intervention may have been too short to detect long-term effects. Secondary analyses suggested possible differences according to obesity and achieved adherence, but were exploratory. Conclusions. The MIND diet is consistent with established cardiometabolic recommendations and can be a part of a broader healthy-ageing strategy. Its specific ability to prevent cognitive decline or dementia remains unconfirmed. Longer randomised trials are required.
- 11 October 2026
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Quality in Sport
- Vol. 77, 76234
Open AccessThe MIND Diet and Cognitive Health in Older Adults: Clinical Evidence, Neuroprotective Mechanisms and Research Gaps—A Narrative Review
Background. The MIND diet combines elements of the Mediterranean and DASH dietary patterns and was developed to support cognitive health. Evidence includes observational, randomised and experimental research. Aim. This narrative review evaluated associations between MIND diet adherence and cognitive outcomes in older adults and compared observational and randomised findings. Methods. PubMed, MEDLINE and Google Scholar were searched through August 2026. Studies addressing cognitive performance, cognitive decline, mild cognitive impairment or dementia were included. Experimental studies were used to assess biological plausibility. Findings were synthesised descriptively. Results. Most observational studies associated greater adherence with better global cognition and memory, slower cognitive decline and lower risks of cognitive impairment and dementia. Experimental evidence supports vascular, metabolic, antioxidant, anti-inflammatory, amyloid-related and gut–brain mechanisms. The principal three-year randomised trial found no significant cognitive or neuroimaging advantage over an active control. Both groups received dietary counselling and caloric restriction and experienced weight loss, while the intervention may have been too short to detect long-term effects. Secondary analyses suggested possible differences according to obesity and achieved adherence, but were exploratory. Conclusions. The MIND diet is consistent with established cardiometabolic recommendations and can be a part of a broader healthy-ageing strategy. Its specific ability to prevent cognitive decline or dementia remains unconfirmed. Longer randomised trials are required.
- Open Access
- 2 October 2026
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Quality in Sport
- Vol. 77, 76229
Autonomic Function in Inflammatory Bowel Disease: A Narrative Review of Objective Assessment and Physiological Monitoring
Introduction and purpose: Autonomic alterations may contribute to the physiological heterogeneity of inflammatory bowel disease (IBD). This review examines objective autonomic assessment in Crohn disease and ulcerative colitis, focusing on physiological phenotyping and longitudinal monitoring. Methods: This focused narrative review synthesizes 25 included studies. Evidence on heart rate variability (HRV), Holter monitoring, cardiovascular reflexes, orthostatic responses, baroreflex function, sudomotor testing, and wearable-derived signals was organized by modality and relationship with disease activity. Brief description of the state of knowledge: HRV was the most studied modality and was associated with clinical, biochemical, and endoscopic activity in selected cohorts. Autonomic alterations may persist during remission and do not consistently correspond to symptoms or inflammatory markers. Reduced HRV alone does not establish autonomic neuropathy. Multimodal testing assesses complementary physiological domains and may yield discordant findings. Wearables offer opportunities for repeated assessment alongside sleep and physical activity, while neuromodulation remains investigational. Heterogeneous protocols, small cohorts, and limited external validation constrain clinical interpretation. Conclusions: Objective autonomic assessment may complement established IBD evaluation in selected patients. The proposed Clinical Algorithm and Physiological Framework are hypothesis-generating and require prospective validation. Standardized multimodal protocols and longitudinal studies are needed. Current evidence does not support autonomic biomarkers as stand-alone tools for disease monitoring or exercise prescription.
- 2 October 2026
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Quality in Sport
- Vol. 77, 76229
Open AccessAutonomic Function in Inflammatory Bowel Disease: A Narrative Review of Objective Assessment and Physiological Monitoring
Introduction and purpose: Autonomic alterations may contribute to the physiological heterogeneity of inflammatory bowel disease (IBD). This review examines objective autonomic assessment in Crohn disease and ulcerative colitis, focusing on physiological phenotyping and longitudinal monitoring. Methods: This focused narrative review synthesizes 25 included studies. Evidence on heart rate variability (HRV), Holter monitoring, cardiovascular reflexes, orthostatic responses, baroreflex function, sudomotor testing, and wearable-derived signals was organized by modality and relationship with disease activity. Brief description of the state of knowledge: HRV was the most studied modality and was associated with clinical, biochemical, and endoscopic activity in selected cohorts. Autonomic alterations may persist during remission and do not consistently correspond to symptoms or inflammatory markers. Reduced HRV alone does not establish autonomic neuropathy. Multimodal testing assesses complementary physiological domains and may yield discordant findings. Wearables offer opportunities for repeated assessment alongside sleep and physical activity, while neuromodulation remains investigational. Heterogeneous protocols, small cohorts, and limited external validation constrain clinical interpretation. Conclusions: Objective autonomic assessment may complement established IBD evaluation in selected patients. The proposed Clinical Algorithm and Physiological Framework are hypothesis-generating and require prospective validation. Standardized multimodal protocols and longitudinal studies are needed. Current evidence does not support autonomic biomarkers as stand-alone tools for disease monitoring or exercise prescription.
- Open Access
- 22 September 2026
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Quality in Sport
- Vol. 74, 76150
Current Therapeutic Strategies for Inflammatory Bowel Disease: A Narrative Review
Background: Inflammatory bowel disease (IBD) is a chronic, relapsing disorder resulting from genetic, immune, microbial, and environmental factors. Therapeutic options have expanded from conventional drugs to biologic agents and targeted small molecules, enabling individualized management. Aim: This narrative review aimed to summarize current treatment strategies for IBD, focusing on conventional therapies, biologics, targeted small molecules, antibiotics, and surgery. Materials and Methods: A narrative literature review was conducted using PubMed, MEDLINE, Google Scholar, and the Journal of Education, Health and Sport (JEHS). Current clinical guidelines, European Medicines Agency (EMA) product information, clinical studies, systematic reviews, and meta-analyses were reviewed, with attention to indications, efficacy, and safety. Results: Biologic agents and targeted small molecules have broadened therapeutic options for moderate-to-severe IBD. Anti-TNF agents, vedolizumab, ustekinumab, selective IL-23 inhibitors, Janus kinase (JAK) inhibitors, and ozanimod act through different pathways and allow treatment to be adapted to disease phenotype, severity, and previous treatment exposure. Conventional therapies, including aminosalicylates, corticosteroids, thiopurines, and methotrexate, remain important in selected situations. Antibiotics retain a role in specific complications, while surgery remains essential in refractory disease and structural complications. Conclusions: Contemporary IBD management follows an individualized, treat-to-target approach aimed at symptom control, objective inflammatory control, mucosal healing, and prevention of long-term complications. Despite therapeutic advances, uncertainties remain regarding treatment sequencing, predictors of response, long-term safety, and access to advanced therapies. Further research is needed to optimize personalized strategies and improve long-term outcomes.
- 22 September 2026
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Quality in Sport
- Vol. 74, 76150
Open AccessCurrent Therapeutic Strategies for Inflammatory Bowel Disease: A Narrative Review
Background: Inflammatory bowel disease (IBD) is a chronic, relapsing disorder resulting from genetic, immune, microbial, and environmental factors. Therapeutic options have expanded from conventional drugs to biologic agents and targeted small molecules, enabling individualized management. Aim: This narrative review aimed to summarize current treatment strategies for IBD, focusing on conventional therapies, biologics, targeted small molecules, antibiotics, and surgery. Materials and Methods: A narrative literature review was conducted using PubMed, MEDLINE, Google Scholar, and the Journal of Education, Health and Sport (JEHS). Current clinical guidelines, European Medicines Agency (EMA) product information, clinical studies, systematic reviews, and meta-analyses were reviewed, with attention to indications, efficacy, and safety. Results: Biologic agents and targeted small molecules have broadened therapeutic options for moderate-to-severe IBD. Anti-TNF agents, vedolizumab, ustekinumab, selective IL-23 inhibitors, Janus kinase (JAK) inhibitors, and ozanimod act through different pathways and allow treatment to be adapted to disease phenotype, severity, and previous treatment exposure. Conventional therapies, including aminosalicylates, corticosteroids, thiopurines, and methotrexate, remain important in selected situations. Antibiotics retain a role in specific complications, while surgery remains essential in refractory disease and structural complications. Conclusions: Contemporary IBD management follows an individualized, treat-to-target approach aimed at symptom control, objective inflammatory control, mucosal healing, and prevention of long-term complications. Despite therapeutic advances, uncertainties remain regarding treatment sequencing, predictors of response, long-term safety, and access to advanced therapies. Further research is needed to optimize personalized strategies and improve long-term outcomes.